1. 124PAssociation of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). (23rd October 2018) Authors: Miller-Phillips, L; Fischer von Weikersthal, L; Kaiser, F; Al-Batran, S-E; Heintges, T; Neureiter, D; Kahl, C; Kullmann, F; Moehler, M; Scheithauer, W; Vazart, C; Fontaine, K; Held, S; Modest, D P; Neumann, J; Jung, A; Kirchner, T; Heinemann, V; Stintzing, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 197TiPGLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study. (24th November 2019) Authors: Xu, R-H; Dongsheng, Z; Ajani, J; Al-Batran, S-E; Bang, Y-J; Catenacci, D; Enzinger, P; Ilson, D; Kim, S; Lordick, F; Shitara, K; Van Cutsem, E; Arozullah, A; Wook Park, J; Shah, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 198TiPSPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study. (24th November 2019) Authors: Yamaguchi, K; Shitara, K; Al-Batran, S-E; Bang, Y-J; Catenacci, D; Enzinger, P; Ilson, D; Kim, S; Lordick, F; Shah, M; Van Cutsem, E; Xu, R-H; Arozullah, A; Wook Park, J; Ajani, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 739PQuality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON. (23rd October 2018) Authors: Schönherr, C; Götze, T O; zur Hausen, G; Reichart, A; Pauligk, C; Schlag, R; Siegler, G M; Dörfel, S; Aldaoud, A; Hahn, L; Schubert, J; Zahn, M-O; Höffkes, H-G; Reiser, M; Koenigsmann, M; Blau, W; Waidmann, O; Homann, N; Trojan, J; Al-Batran, S-E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 778TiPIpilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217). (23rd October 2018) Authors: Goekkurt, E; Binder, M; Lorenzen, S; Thuss-Patience, P C; Al-Batran, S-E; Hinke, A; Hegewisch-Becker, S; Nilsson, S; Bokemeyer, C; Stein, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗